IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Acquired by Cibc World Markets Corp

Cibc World Markets Corp boosted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 13.1% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,744 shares of the company's stock after purchasing an additional 1,709 shares during the period. Cibc World Markets Corp's holdings in IDEXX Laboratories were worth $6,096,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently bought and sold shares of the business. Jensen Investment Management Inc. grew its holdings in IDEXX Laboratories by 11.5% during the 4th quarter. Jensen Investment Management Inc. now owns 9,020 shares of the company's stock worth $3,729,000 after acquiring an additional 930 shares in the last quarter. Glenview Trust co lifted its position in shares of IDEXX Laboratories by 152.8% during the fourth quarter. Glenview Trust co now owns 16,812 shares of the company's stock worth $6,951,000 after purchasing an additional 10,162 shares during the last quarter. Centurion Wealth Management LLC grew its stake in IDEXX Laboratories by 16.4% in the fourth quarter. Centurion Wealth Management LLC now owns 846 shares of the company's stock worth $350,000 after purchasing an additional 119 shares in the last quarter. Choate Investment Advisors increased its holdings in IDEXX Laboratories by 1.9% in the fourth quarter. Choate Investment Advisors now owns 2,091 shares of the company's stock valued at $865,000 after buying an additional 39 shares during the last quarter. Finally, Natixis Advisors LLC increased its holdings in IDEXX Laboratories by 4.6% in the fourth quarter. Natixis Advisors LLC now owns 45,171 shares of the company's stock valued at $18,675,000 after buying an additional 1,997 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Remove Ads

Wall Street Analyst Weigh In

IDXX has been the topic of a number of research analyst reports. Bank of America increased their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Leerink Partnrs raised shares of IDEXX Laboratories to a "strong-buy" rating in a report on Monday, December 2nd. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating on the stock in a report on Wednesday, January 29th. Barclays raised their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Finally, StockNews.com downgraded shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday, March 15th. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $533.75.

Insider Buying and Selling at IDEXX Laboratories

In related news, EVP George Fennell sold 9,986 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the transaction, the executive vice president now directly owns 8,176 shares of the company's stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director M Anne Szostak sold 3,000 shares of the firm's stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $465.94, for a total value of $1,397,820.00. Following the completion of the sale, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.11% of the stock is owned by company insiders.

IDEXX Laboratories Stock Performance

NASDAQ:IDXX traded up $2.61 during mid-day trading on Monday, hitting $423.60. The stock had a trading volume of 616,827 shares, compared to its average volume of 552,334. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28. The company has a 50 day simple moving average of $437.36 and a 200-day simple moving average of $444.76. The stock has a market capitalization of $34.34 billion, a price-to-earnings ratio of 39.70, a P/E/G ratio of 3.41 and a beta of 1.39. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $548.88.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.